Lundbeck, a pharmaceutical company, shared new research about eptinezumab at the 2025 International Headache Congress in São Paulo. The data shows that this medicine helps people with severe chronic migraines over a long period. The company presented six studies, including three detailed talks about eptinezumab and another drug called Lu AG09222. The most important findings came from follow-up studies of two earlier trials: RESOLUTION and SUNSET. In the RESOLUTION trial, patients with chronic migraines and frequent medicine use saw a lasting drop in migraine days per month. About half of the patients had at least a 50% reduction in migraine days, with an average decrease of nine migraine days over 12 weeks. The SUNSET trial, which followed Japanese patients for 60 weeks, confirmed that eptinezumab keeps working well over time. By weeks 49 to 60, 35.7% of patients had a 50% reduction in migraine days, and more people were seeing even greater improvements. The medicine was safe in both studies, with no new safety concerns reported. Dr. Johan Luthman, Lundbeck’s Head of Research, said, ‘Patients need treatments that not only work quickly but also keep working. These studies show that eptinezumab helps people with chronic migraines stay migraine-free for a long time.’ This research supports eptinezumab as a strong, long-lasting treatment option for people with chronic migraines.